Concepedia

Khalid Mezzi

KM

Statistics

Publications

7

Citations

207

H-Index

7

Active since

2016

Affiliations

Amgen (United States)(Current)

Hackensack University Medical Center

National and Kapodistrian University of Athens

Wilhelminen Hospital

Cornell University

Khalid Mezzi is an author at Amgen (United States) specializing in multiple myeloma, multiple myeloma therapy, and multiple myeloma treatment.

Publications per year

2016–2021

7

Publications

7

Carfilzomib vs bortezomib in patients with multiple myeloma and renal failure: a subgroup analysis of ENDEAVOR

Meletios Α. Dimopoulos, David S. Siegel, Darrell White et al. · Blood · 2018 · 43 citations · Full text

, , +15

Recommendations on Eliminating Racial Disparities in Multiple Myeloma Therapies: A Step toward Achieving Equity in Healthcare

Nicole Gormley, Lola A. Fashoyin‐Aje, Trevan Locke et al. · Blood Cancer Discovery · 2021 · 41 citations · Full text

, , +16

Incidence and risk of hypertension in patients newly treated for multiple myeloma: a retrospective cohort study

Ajai Chari, Khalid Mezzi, Shao Zhu et al. · BMC Cancer · 2016 · 37 citations · Full text

, , +8

Efficacy and safety of carfilzomib-based regimens in frail patients with relapsed and/or refractory multiple myeloma

Thierry Façon, Rubén Niesvizky, María‐Victoria Mateos et al. · Blood Advances · 2020 · 31 citations · Full text

, , +16

Cardiovascular events during carfilzomib therapy for relapsed myeloma: practical management aspects from two case studies

Andrzej Jakubowiak, Jeanne M. DeCara, Khalid Mezzi · Hematology · 2017 · 20 citations · Full text

, , +15

1–5 of 7